Wouter Plattel
dr.
As a hematologist I am always looking for new development that might improve patient care. My main research focus is on patients with Hodgkin lymphoma and multiple myeloma. I am involved in both translational and clinical studies. In cooperation with the Pathology, I am active in the field of biomarkers, such as TARC in Hodgkin lymphoma. For the design, development and execution of clinical trials, I am an active member of both international (EORTC) and national (HOVON) organizations. For example, I am the national PI of the EORTC COBRA trial in Hodgkin lymphoma. Moreover, I am co-PI of the translational research in two international trials. In addition, I am part of the Dutch guideline writing committee for Hodgkin lymphoma. In myeloma, I am investigating innovative treatment options to improve outcome.
Improved survival for adolescents and young adults with Hodgkin lymphoma and continued high survival for children in the Netherlands: a population-based study during 1990-2015
Published in: British Journal of Haematology
Access to document
10.1111/bjh.16491
document
Population-based studies that assess long-term patterns of incidence, major aspects of treatment and survival are virtually lacking for Hodgkin lymphoma (HL) at a younger age. This study assessed the progress made for young patients with HL (<25 years at diagnosis) in the Netherlands during 1990-2015. Patient and tumour characteristics were extracted from the population-based Netherlands Cancer Registry. Time trends in incidence and mortality rates were evaluated with average annual percentage change (AAPC) analyses. Stage at diagnosis, initial treatments and site of treatment were studied in relation to observed...
Ardine M J Reedijk, Eline A M Zijtregtop, Jan Willem W Coebergh, Friederike A G Meyer-Wentrup, Konnie M Hebeda, C Michel Zwaan, Geert O R Janssens, Rob Pieters, Wouter J Plattel, Avinash G Dinmohamed, Josée M Zijlstra, Leontien C M Kremer, Pieternella J Lugtenburg, Auke Beishuizen, Henrike E Karim-Kos
Molecular imaging in lymphoma beyond F-18-FDG-PET: understanding the biology and its implications for diagnostics and therapy
Published in: Lancet Haematology
Access to document
10.1016/S2352-3026(20)30065-X
document
Mature lymphoproliferative diseases are a heterogeneous group of neoplasms arising from different stages of B-cell and T-cell development. With improved understanding of the molecular processes in lymphoma and novel treatment options, arises a growing need for the molecular characterisation of tumours. Molecular imaging with single-photon-emission CT and PET using specific radionuclide tracers can provide whole-body information to investigate cancer biology, to evaluate phenotypic heterogeneity, to identify resistance to targeted therapy, and to assess the biodistribution of drugs in patients. In this Review, we evaluate the existing literature on...
Xaver U. Kahle, Filipe M. Montes de Jesus, Andor W. J. M. Glaudemans, Marjolijn N. Lub-de Hooge, Annelies Jorritsma-Smit, Wouter J. Plattel, Tom van Meerten, Arjan Diepstra, Anke van den Berg, Thomas C. Kwee, Walter Noordzij, Elisabeth G. E. de Vries, Marcel Nijland
Cell-free DNA as biomarker in Hodgkin lymphoma patients
Published in: Klinische Pädiatrie
Access to document
10.1055/s-0040-1701844
Treatment of early favorable hodgkin lymphoma
Published in: Hematologic Malignancies
Access to document
10.1007/978-3-030-32482-7_11
document
Early favorable Hodgkin lymphoma is defined as Ann Arbor stage I and II Hodgkin lymphoma without clinical risk factors. Historically, early favorable Hodgkin lymphoma became highly curable with large radiotherapy fields but at the cost of high early and late toxicity resulting in reduced long-term survival. The successful introduction of multiagent chemotherapy in Hodgkin lymphoma made it possible to combine chemotherapy with radiotherapy in smaller doses and fields. Last decades, efforts have been made to find optimal chemotherapy treatment with limited cycles (2–3) of ABVD combined with limited...
Wouter Plattel, Pieternella Lugtenburg
Relationship between semiquantitative 18F-fluorodeoxyglucose positron emission tomography metrics and necrosis in classical Hodgkin lymphoma
Published in: Scientific Reports
Access to document
10.1038/s41598-019-47453-5
document
Semiquantitative 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG PET) parameters have been proposed as prognostic markers in classical Hodgkin lymphoma (cHL). In non-Hodgkin lymphoma necrosis as assessed by 18F-FDG PET or computed tomography (CT) (necrosisvisual) correlates with an adverse prognosis. We investigated whether semiquantitative 18F-FDG PET metrics correlate with necrosisvisual, determined the incidence of necrosisvisual and explored the prognostic impact of these factors in cHL. From 87 cHL cases treated with ABVD, (escalated) BEACOPP or CHOP chemotherapy between 2010 and 2017, 71 had both a NEDPAS/EARL accredited 18F-FDG PET and...
X U Kahle, F M Montes de Jesus, T C Kwee, T van Meerten, A Diepstra, S Rosati, A W J M Glaudemans, W Noordzij, W J Plattel, M Nijland